Herbal treatment for dysmenorrhea

Effect Of Zafran In Primary Dysmenorrhea- Pre & Post Interventional Study without control group

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/04/052139

Enrollment

Registered

2023-04-28

Start date

Unknown

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N944- Primary dysmenorrhea

Interventions

Intervention1: Cap Zafran 250mg BD: cap zafran 250mg twice daily for 5 days. Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: Painful menstrual cycles with or without associated symptoms(nausea, vomitting, fatigue)

Exclusion criteria

Exclusion criteria: Patients with systemic disease HTN, DM-II. Patients with pelvic pathologies(Fibroid, PID, Endometriosis, PCOS, Malignancies) Patients with acute abdominal conditions(Appendicitis, Renal colic) Patients on HRT previous three months. Lactating women.

Design outcomes

Primary

Measure	Time frame
Subjective: Painful menstruation mild to moderate as per VAS.Timepoint: 90 days	—

Secondary

Measure	Time frame
Objective: VAS & VMS, SF-12(Qol)Timepoint: 90 days	—

Countries

India

Contacts

Public ContactProf Wajeeha Begum

National Institute of Unani Medicine

drwajeehanium@gmail.com9972550185

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026